PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

PHAXIAM Reports Third-Quarter 2024 Financial Information

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.

PHAXIAM Provides Business and Financial Update For the First Half of 2024

Results of the Combined General Meeting of 28 June 2024

PHAXIAM provides Business and Financial Update for the First Quarter of 2024

PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus

PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)

PHAXIAM Therapeutics S.A. (ERYFF) Q4 2023 Earnings Call Transcript

PHAXIAM Announces 2023 Full-Year Results and Provides Business Update

PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024

PHAXIAM Therapeutics S.A. (PHXM) Q3 2023 Earnings Call Transcript

PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation

PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains

PHAXIAM Receives Compliance Notice from Nasdaq

Rapport Financier Semestriel 30 Juin 2023 PHAXIAM

PHAXIAM Provides Business and Financial Update For the First Half of 2023

PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences